0000000000668954

AUTHOR

G. Rivard

showing 2 related works from this author

Stormwater Source Control as a Strategy for Sustainable Development: State of the Practice and Perceived Trends

2005

The primary objective of the paper is to draw upon the experiences acquired in many parts of the world to provide an up-to-date summary of the state of the practice for source control techniques and approaches, in a sustainable development context. After a discussion of the prevailing context for urban drainage approaches, three main themes covering techniques and design criteria, institutional aspects and performance issues are discussed relative to source control implementation. The discussion is based on findings from the compilation and analysis of available literature, recently developed databases, the experience of the different members of the SOCOMA group and recent research on desig…

sustainable developmentBMPs design criteriaBMPs effectivenessintegrated water managementtormwater source control
researchProduct

Factor VIII products and inhibitor development in severe hemophilia A

2013

For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity, <0.01 IU per milliliter) who were born between 2000 and 2010 and collected data on all clotting-factor administration for up to 75 exposure days. The primary outcome was inhibitor development, which was defined as at least two positive inhibitor tests with decreased in vivo recovery of factor VIII levels. Inhibitory antibodies developed in 177 of th…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyHemophilia ABethesda unitGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineVon Willebrand factorIn vivoInternal medicinevon Willebrand FactormedicineHumansCumulative incidenceChildFactor VIIIHematologybiologybusiness.industryLiterGeneral Medicine3. Good healthTiterImmunologybiology.proteinAntibodybusiness030215 immunologyNew England journal of medicine
researchProduct